

**SUPPLEMENTARY INFORMATION:** The sole source award will support the government of Rwanda's vision of achieving and maintaining HIV epidemic control and the UNAIDS goal of ending HIV/AIDS as a public health threat by 2030.

RBC is in a unique position to conduct this work, as it possesses not only the mandate but also has the capacities to manage donor funds efficiently and in accordance with PEPFAR principles and United State Government regulations. All health workers implementing PEPFAR-supported HIV clinical services including HIV testing, Antiretroviral Therapy, TB/HIV, prevention of mother to child transmission, and laboratory services are Ministry of Health (MOH) staff. All health facilities where PEPFAR-supported services are offered are under RBC accreditation and authorization. RBC is successfully coordinating HIV services in all health facilities countrywide. It is the only entity capable of providing comprehensive services and integrating HIV into the national health system to cover all Rwanda districts at each level.

#### Summary of the Award

*Recipient:* Rwanda Biomedical Center (RBC).

*Purpose of the Award:* The purpose of this award is to support a sustainable, affordable, integrated, and country-led HIV/AIDS clinical and public health program in Rwanda.

*Amount of Award:* For RBC, the approximate year 1 funding amount will be \$17,500,000 in Federal Fiscal Year (FFY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

*Authority:* This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) (22 U.S.C. 7601, *et seq.*) and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013).

*Period of Performance:* The period for this award will be September 30, 2024, through September 29, 2029.

Dated: March 13, 2024.

#### Jamie Legier,

*Acting Director, Office of Grants Services, Centers for Disease Control and Prevention.*

[FR Doc. 2024–05776 Filed 3–18–24; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Award of a Sole Source Cooperative Agreement To Fund National Tuberculosis Control Program (NTCP)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award(s) of approximately \$3,000,000, for Year 1 funding to NTCP. The award will improve the capacity of the health system at national, regional, district, and facility levels to provide an effective public health response for Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection in Cameroon, reduce disease burden, and contribute to achieving and sustaining epidemic control. Funding amounts for years 2–5 will be set at continuation.

**DATES:** The period for this award will be September 30, 2024, through September 29, 2029.

**FOR FURTHER INFORMATION CONTACT:** F.E. Harrison, Center for Global Health, Centers for Disease Control and Prevention, telephone: (404) 639–6095, email: [ckv3@cdc.gov](mailto:ckv3@cdc.gov).

**SUPPLEMENTARY INFORMATION:** This sole source award will accelerate progress in reducing the burden of TB and TB/HIV co-infection in Cameroon through a multistakeholder approach.

NTCP is in a unique position to conduct this work, as it is the only institution that has the legal mandate to develop and implement the national strategic plan for TB control, which aims to reduce the morbidity and mortality associated with TB.

#### Summary of the Award

*Recipient:* National Tuberculosis Control Program (NTCP).

*Purpose of the Award:* The purpose of this award is to improve the capacity of the health system at national, regional, district, and facility levels to provide an effective public health response for TB and HIV co-infection in Cameroon, reduce disease burden, and contribute to achieving and sustaining epidemic control.

*Amount of Award:* For NTCP, the approximate year 1 funding amount will be \$3,000,000 in Federal Fiscal Year

(FFY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

*Authority:* This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) (22 U.S.C. 7601, *et seq.*) and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013).

*Period of Performance:* The period for this award will be September 30, 2024, through September 29, 2029.

Dated: March 13, 2024.

#### Jamie Legier,

*Acting Director, Office of Grants Services, Centers for Disease Control and Prevention.*

[FR Doc. 2024–05772 Filed 3–18–24; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Award of a Sole Source Cooperative Agreement To Fund World Health Organization (WHO)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$20,000,000, for Year 1 funding to WHO. This award will support the development of global guidelines and provide technical assistance through WHO to aid PEPFAR-supported countries to meet the 95–95–95 targets and achieve program sustainability by 2030. Funding amounts for years 2–5 will be set at continuation.

**DATES:** The period for this this award will be September 30, 2024, through September 29, 2029

**FOR FURTHER INFORMATION CONTACT:** Francheskie Velez, Center for Global Health, Centers for Disease Control and Prevention, 1600 Clifton Road NE MS–E39 Atlanta, GA 30329, telephone: 404.245.5639, e-Mail: [gpg2@cdc.gov](mailto:gpg2@cdc.gov).

**SUPPLEMENTARY INFORMATION:** The sole source award will support efforts to improve surveillance, prevention, care, and treatment of HIV, Tuberculosis (TB), sexually transmitted infection

(STIs), viral hepatitis, and associated chronic co-infections and noncommunicable diseases (NCDs); promote health equity; increase sustainability of programs; strengthen public health systems and health security; and follow science.

WHO is in a unique position to conduct this work, as it is the sole international global health organization responsible for issuing normative standard and guidelines for implementation of health programs including HIV/AIDS within the UN system. No other organization has the authority to issue international standards for health in the UN system as denoted by the WHO constitution signed in 1948.

#### Summary of the Award

*Recipient:* World Health Organization (WHO).

*Purpose of the Award:* The purpose of this award is to support the development of global guidelines and provide technical assistance through WHO to aid PEPFAR-supported countries to meet the 95–95–95 targets and achieve program sustainability by 2030. In alignment with the 2022 PEPFAR Five-Year Strategy.

*Amount of Award:* For WHO, the approximate year 1 funding amount will be \$20,000,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

*Authority:* This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) (22 U.S.C. 7601, *et seq.*) and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013). Additionally, this program is authorized under section 307 of the Public Health Service Act (42 U.S.C. 242l), as amended and section 301(a) of the Public Health Service Act (42 U.S.C. 241(a)), as amended.

#### Non-PEPFAR Funding

Additionally, this program is authorized under the Public Health Service Act 42 CFR part 51b—Project Grants for Preventive Health Services section 318 (42 U.S.C. 247c) section 318 (42 U.S.C. 247c) Sexually transmitted diseases; prevention and control projects; sections 301(a), 317N, and 318 of the Public Health Service Act (42 U.S.C. 241(a), 247b–15, and 247c).

*Period of Performance:* The period for this award will be September 30, 2024, through September 29, 2029.

Dated: March 13, 2024.

**Jamie Legier,**

*Acting Director, Office of Grants Services,  
Centers for Disease Control and Prevention.*

[FR Doc. 2024–05774 Filed 3–18–24; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Award of a Sole Source Cooperative Agreement To Fund National Health Laboratory Service (NHLS)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award(s) of approximately \$5,000,000, for Year 1 funding to NHLS. The(se) award(s) will strengthen laboratory systems for improved access to sustainable delivery of quality laboratory services and promote rational use of diagnostic services in South Africa through above site interventions. Funding amounts for years 2–5 will be set at continuation.

**DATES:** The period for this award will be September 30, 2024, through September 29, 2029.

**FOR FURTHER INFORMATION CONTACT:**

Artur Ramos, Center for Global Health, Centers for Disease Control and Prevention, 100 Totius Street, Groenkloof, Pretoria, telephone: 3108483712, e-Mail: [cer9@cdc.gov](mailto:cer9@cdc.gov).

**SUPPLEMENTARY INFORMATION:** The(se) sole source award(s) will address gaps in line with PEPFAR strategies and the Government of South Africa's key priority areas that need continued PEPFAR support. This includes developing and reviewing laboratory policies, strategic plans, and governance structures to expand diagnostic health equity and response to Human Immunodeficiency Virus (HIV), Tuberculosis (TB) and related public health needs. It also includes prioritizing technical and systems advancements to increase operational efficiencies and improve service delivery as well as supporting an environment that facilitates and endorses integration, ownership, and

sustainable transition of PEPFAR-funded laboratory activities to NHLS and the National Department of Health.

NHLS is in a unique position to conduct this work, as it is the sole provider of diagnostic pathology services to the public sector in South Africa and has been mandated by the government of South Africa under the National Health Laboratory Service Act, 2000 to provide quality, affordable, and sustainable laboratory and related public health services. Quality laboratory testing is an essential building block of the HIV clinical cascade as accurate and timely clinical laboratory services will facilitate the earlier diagnosis of HIV, staging, identification of adverse drug events and opportunistic infections, and monitoring the response of individual patients to therapy, including identification of treatment failures.

#### Summary of the Award

*Recipient:* National Health Laboratory Service (NHLS).

*Purpose of the Award:* The purpose of this award is to strengthen laboratory systems for improved access to sustainable delivery of quality laboratory services and promote rational use of diagnostic services in South Africa through above site interventions.

*Amount of Award:* For NHLS, the approximate year 1 funding amount will be \$5,000,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

*Authority:* This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) (22 U.S.C. 7601, *et seq.*) and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013). Additionally, this program is authorized under section 307 of the Public Health Service Act (42 U.S.C. 242l), as amended and section 301(a) of the Public Health Service Act (42 U.S.C. 241(a)), as amended.

*Period of Performance:* The period for this award will be September 30, 2024, through September 29, 2029.

Dated: March 13, 2024.

**Jamie Legier**

*Acting Director, Office of Grants Services,  
Centers for Disease Control and Prevention.*

[FR Doc. 2024–05777 Filed 3–18–24; 8:45 am]

**BILLING CODE 4163–18–P**